by The acute repetitive seizures market comprises treatments used primarily for controlling bouts of acute repetitive seizures. These products are developed specifically for the management of seizures that occur within a brief period. Seizures that reoccur intermittently within a 24-hour time frame are referred to as acute repetitive seizures. Certain anti-epileptic drugs have demonstrated efficacy in controlling these seizures and improving the quality of life in epilepsy patients.
The global acute repetitive seizures market size is estimated to be valued at US$ 3.10 Bn in 2024 and is expected to exhibit a CAGR of 12.% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the acute repetitive seizures market are Neurelis, Inc., Bausch Health Companies Inc., Alexza Pharmaceuticals, Inc., VERITON PHARMA, UCB S.A., Takeda Pharmaceutical Company Limited, Pfizer Inc., Sanofi, GSK plc, Eisai Co., Ltd., H. Lundbeck A/S, Cognizance Biomarkers, LLC.
The market provides ample opportunities for players involved in developing new treatment options for acute repetitive seizures. Research focusing on expanded indications of existing drugs and novel mechanism of actions are anticipated to boost market revenues.
Stringent regulations and approval processes across key regions may slow down the approval timelines. However, higher disease incidence rates in developing nations will drive geographic expansion plans of major market players in the coming years.
Market Drivers
The increasing prevalence of epilepsy worldwide is a key factor accelerating the demand for anti-seizure medications. Acute repetitive seizures are commonly associated with temporal lobe epilepsy, which accounts for the majority of epilepsy cases. According to the World Health Organization, over 50 million people suffer from epilepsy globally. Unmet needs in developing specialized acute repetitive seizure treatments is further augmenting research & development in this domain.
PEST Analysis
Political: Government regulations regarding the sale and use of prescription drugs for seizure treatment could impact the market.
Economic: Growth of the economy and disposable income levels determine spending on healthcare and prescription drugs for treatments like acute repetitive seizures.
Social: Increased awareness about epilepsy and acute repetitive seizures is encouraging more people to seek proper diagnosis and treatment.
Technological: Advancements in drug delivery methods and development of novel anti-epileptic drugs are expanding treatment options for patients suffering from acute repetitive seizures.
Acute Repetitive Seizures Market Regional Analysis where the acute repetitive seizures market is concentrated in terms of value are North America and Europe. These developed markets have established healthcare systems and people are willing to pay for advanced treatment options.
The Asia Pacific region is expected to be the fastest growing market for acute repetitive seizures over the forecast period from 2024 to 2031. Factors such as rising disposable incomes, growing medical infrastructure and increasing awareness are boosting demand for anti-epileptic drugs in developing countries of Asia Pacific. China and India offer huge growth potential due to their large population bases.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
About Author - Ravina Pandya
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals. LinkedIn Profile
